PMID- 34295421
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1810-6838 (Print)
IS  - 2073-4735 (Electronic)
IS  - 1810-6838 (Linking)
VI  - 17
IP  - 2
DP  - 2021 Jun
TI  - Minimal clinically important difference in idiopathic pulmonary fibrosis.
PG  - 200345
LID - 10.1183/20734735.0345-2020 [doi]
LID - 200345
AB  - Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing lung 
      disease with an estimated median survival of 2-5 years and a significant impact 
      on quality of life (QoL). Current approved medications, pirfenidone and 
      nintedanib, have shown a reduction in annual decline of forced vital capacity but 
      no impact on QoL. The minimal clinically important difference (MCID) is a 
      threshold value for a change in a parameter that is considered meaningful by the 
      patient rather than solely relying on statistically significant change in the 
      parameter. This review provides a brief overview of the MCID methodology along 
      with detailed discussion of reported MCID values for commonly used physiological 
      measures and patient-reported outcome measures in IPF. While there is no gold 
      standard methodology for determining MCID, there are certain limitations in the 
      MCID literature in IPF, mainly the choice of death, hospitalisation and pulmonary 
      function tests as sole anchors, and pervasive use of distribution-based methods 
      which do not take into account the patient's input. There is a critical need to 
      identify accurate thresholds of outcome measures that reflect patient's QoL over 
      time in order to more precisely design and evaluate future clinical trials and to 
      develop algorithms for patient-oriented management of IPF in outpatient clinics. 
      EDUCATIONAL AIMS: To understand the concept of MCID and the methods used to 
      determine these values.To understand the indications and limitations of MCID 
      values in IPF.
CI  - Copyright (c)ERS 2021.
FAU - Kang, Mohleen
AU  - Kang M
AUID- ORCID: 0000-0003-0471-2884
AD  - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory 
      University School of Medicine, Atlanta, GA, USA.
FAU - Marts, Lucian
AU  - Marts L
AD  - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory 
      University School of Medicine, Atlanta, GA, USA.
FAU - Kempker, Jordan A
AU  - Kempker JA
AUID- ORCID: 0000-0002-6830-5201
AD  - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory 
      University School of Medicine, Atlanta, GA, USA.
FAU - Veeraraghavan, Srihari
AU  - Veeraraghavan S
AD  - Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory 
      University School of Medicine, Atlanta, GA, USA.
LA  - eng
GR  - K08 HS025240/HS/AHRQ HHS/United States
GR  - T32 HL116271/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - England
TA  - Breathe (Sheff)
JT  - Breathe (Sheffield, England)
JID - 101231007
PMC - PMC8291912
COIS- Conflict of interest: M. Kang reports grants from National Heart, Lung, and Blood 
      Institute (Division T32 grant: 5T32HL116271-07; PI Dr. David Guidot), during the 
      conduct of the study. Conflict of interest: L. Marts reports grants from aTyr 
      Pharma, outside the submitted work. Conflict of interest: J.A. Kempker reports 
      grants from Agency for Healthcare Quality and Research (K08HS025240) and personal 
      fees from Grifols, Inc, outside the submitted work. Conflict of interest: S. 
      Veeraraghavan reports personal fees from Boehringer Ingelheim (Advisory board), 
      and research support grants from Fibrogen, Bellerophon, Biogen, Nitto Denko, 
      Pliant, Galapagos and Galecto, outside the submitted work.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2021/06/01
CRDT- 2021/07/23 06:48
PHST- 2020/12/30 00:00 [received]
PHST- 2021/03/14 00:00 [accepted]
PHST- 2021/07/23 06:48 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2021/06/01 00:00 [pmc-release]
AID - EDU-0345-2020 [pii]
AID - 10.1183/20734735.0345-2020 [doi]
PST - ppublish
SO  - Breathe (Sheff). 2021 Jun;17(2):200345. doi: 10.1183/20734735.0345-2020.